Clomiphene-Resistant Anovulatory Infertility in PCOS: Confirming the Diagnosis and Choosing the Next Step
A 32-year-old G0 with a BMI of 33 kg/m2 has had oligomenorrhea since menarche, with cycles every 60-90 days, and hirsutism. She has been trying to conceive for 14 months. Total testosterone is mildly elevated, TSH and prolactin are normal, HbA1c is 5.6%, and pelvic ultrasound shows polycystic ovarian morphology. Her partner's semen analysis is normal. Her primary care physician prescribed clomiphene 50 mg for one cycle and 100 mg for two cycles; mid-luteal progesterone levels were 0.9, 1.1, and 0.8 ng/mL, so she never ovulated. She has never had a hysterosalpingogram. She now requests in vitro fertilization, saying she has already failed three treatments and does not want to wait any longer. She is a non-smoker and takes no other medications.
1. Before escalating treatment, what else needs to be evaluated, and how do you counsel her about the clomiphene failures?
Read the worked answer
What is missing. Tubal status is unknown; a hysterosalpingogram or saline infusion sonohysterogram is required before any further fertility treatment, because a hydrosalpinx both prevents conception and reduces IVF success, and would change the recommendation. Confirm the partner's semen analysis is current and complete. Review blood pressure, lipids, and consider an oral glucose tolerance test given the BMI; screen for obstructive sleep apnea and for endometrial hyperplasia, since chronic anovulation means unopposed estrogen exposure. Ensure she has had withdrawal bleeding with a progestin and that her endometrium is protected.
Counseling about the clomiphene. She did not fail three different treatments; she failed one drug. Moreover, 100 mg is not the maximum dose (150 mg is), so her clomiphene course was not optimized. Clomiphene also has a real failure rate in PCOS, and the more important point is that it is no longer first-line: randomized trial data show letrozole produces higher live birth rates than clomiphene in PCOS, with fewer multiple pregnancies. Her lack of ovulation on clomiphene actually predicts a reasonable chance with letrozole.
Lifestyle. A 5-10% weight loss can restore ovulation in a substantial proportion of women with PCOS and improves pregnancy outcomes; this is worth discussing even though she is impatient, framed as an adjunct rather than a delay. Also explain that ovulation induction with timed intercourse is far less invasive and costly than IVF and should be tried first when tubes are patent and semen is normal.
2. Outline a stepwise ovulation induction plan for her, including drug choice, dosing, monitoring, and the risks you would discuss.
Read the worked answer
First step: letrozole. Start letrozole 2.5-5 mg daily for five days beginning on day 2-5 of a induced withdrawal bleed. If anovulation persists, increase to 7.5 mg in the next cycle. Confirm ovulation with a mid-luteal progesterone (above roughly 3 ng/mL) or with serial ultrasound, and time intercourse or perform intrauterine insemination if indicated. Adding metformin is reasonable, especially with insulin resistance or a BMI above 35; it improves ovulation and may reduce miscarriage, but is not a substitute for an ovulatory agent.
Monitoring and risks. With oral agents, ultrasound on cycle day 12-14 or progesterone on day 21 suffices to confirm ovulation and to check follicle number. Discuss multiple pregnancy (roughly 3-8% with letrozole, higher with clomiphene), ovarian hyperstimulation (rare with oral agents), hot flashes, mood changes, and the antiestrogenic effect of clomiphene on endometrial thickness and cervical mucus. Explain that letrozole appears to carry less multiple-pregnancy risk than clomiphene and that a singleton pregnancy is the goal.
If letrozole fails. Options are adding metformin, switching to gonadotropins with a low-dose step-up protocol, laparoscopic ovarian drilling, or IVF. Before gonadotropins, she needs documented tubal patency. Set expectations: oral agents produce live births in a large share of PCOS patients over 6 ovulatory cycles, and it is reasonable to try up to six ovulatory cycles before moving to IVF. Do not let her proceed to IVF without an HSG or without ensuring the endometrium is protected during anovulatory cycles.
3. If she does not ovulate on letrozole 7.5 mg, has a normal HSG and a normal semen analysis, what are the reasonable next options and how do you choose between them?
Read the worked answer
Option 1: gonadotropins. Low-dose step-up gonadotropin therapy gives the highest ovulation rates among non-IVF options in clomiphene- and letrozole-resistant PCOS. Start at a low dose (for example 37.5-50 IU daily) and increase slowly, with ultrasound monitoring to aim for one dominant follicle. Discuss the 15-20% multiple-pregnancy rate and the real risk of ovarian hyperstimulation syndrome; these are the main reasons to prefer single-follicle protocols and to cancel cycles with excessive follicular development.
Option 2: laparoscopic ovarian drilling. It induces ovulation in roughly half to two-thirds of women, avoids hyperstimulation and multiple pregnancy, and may be repeated, but it requires surgery and anesthesia, carries adhesion and bleeding risks, may reduce ovarian reserve, and is less effective with a high BMI.
Option 3: IVF. This is the most effective per cycle and allows single-embryo transfer, which controls multiple pregnancy, but it is costly, requires daily injections and monitoring, and carries hyperstimulation risk. Her BMI will reduce success and increase obstetric risk.
Choosing. Given her age of 32, a normal HSG and semen analysis, and the fact that she has never had a properly conducted ovulatory trial, I would recommend a monitored gonadotropin trial of three to six cycles, with metformin and weight loss as adjuncts, before IVF. If she wants the highest chance per unit time and understands the cost, IVF with single-embryo transfer is a legitimate preference. In either case, counsel her about pregnancy risks with PCOS and obesity, including gestational diabetes, preeclampsia, and preterm birth, and about endometrial protection.